Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition-Reference-Cited by-同舟云学术

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Published:2020-10 Issue:2 Volume:183 Page:363-376.e13
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Nabet Barzin Y.^ORCID,Esfahani Mohammad S.,Moding Everett J.^ORCID,Hamilton Emily G.^ORCID,Chabon Jacob J.^ORCID,Rizvi Hira,Steen Chloe B.^ORCID,Chaudhuri Aadel A.^ORCID,Liu Chih Long,Hui Angela B.,Almanza Diego^ORCID,Stehr Henning,Gojenola Linda,Bonilla Rene F.,Jin Michael C.^ORCID,Jeon Young-Jun,Tseng Diane^ORCID,Liu Cailian,Merghoub Taha,Neal Joel W.^ORCID,Wakelee Heather A.^ORCID,Padda Sukhmani K.,Ramchandran Kavitha J.,Das Millie,Plodkowski Andrew J.^ORCID,Yoo Christopher,Chen Emily L.,Ko Ryan B.^ORCID,Newman Aaron M.,Hellmann Matthew D.^ORCID,Alizadeh Ash A.^ORCID,Diehn Maximilian

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference45 articles.

1. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer;Anagnostou;Cancer Res.,2019

2. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer;Anagnostou;Nat. Cancer,2020

3. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma;Auslander;Nat. Med.,2018

4. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC;Camidge;Nat. Rev. Clin. Oncol.,2019

5. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients;Chabon;Nat. Commun.,2016

Cited by 227 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer;Radiotherapy and Oncology;2024-09

2. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab;Journal of Clinical Oncology;2024-08-28

3. Community assessment of methods to deconvolve cellular composition from bulk gene expression;Nature Communications;2024-08-27

4. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study;Nature Communications;2024-08-23

5. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08